
[Federal Register: March 19, 2010 (Volume 75, Number 53)]
[Rules and Regulations]               
[Page 13225]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr19mr10-4]                         

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 522

[Docket No. FDA-2010-N-0002]

 
Implantation or Injectable Dosage Form New Animal Drugs; Flunixin

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is amending the animal 
drug regulations to reflect approval of an original abbreviated new 
animal drug application (ANADA) filed by Cross Vetpharm Group Ltd. The 
ANADA provides for the use of flunixin meglumine injectable solution in 
swine.

DATES: This rule is effective March 19, 2010.

FOR FURTHER INFORMATION CONTACT: John K. Harshman, Center for 
Veterinary Medicine (HFV-170), Food and Drug Administration, 7500 
Standish Pl., Rockville, MD 20855, 240-276-8197, e-mail: 
john.harshman@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: Cross Vetpharm Group Ltd., Broomhill Rd., 
Tallaght, Dublin 24, Ireland, filed ANADA 200-489 that provides for use 
of FLUNAZINE-S (flunixin meglumine) Injectable Solution in swine for 
control of pyrexia associated with swine respiratory disease. Cross 
Vetpharm Group Ltd.'s FLUNAZINE-S is approved as a generic copy of 
BANAMINE-S, sponsored by Schering-Plough Animal Health Corp. under NADA 
101-479. The ANADA is approved as of March 1, 2010, and the regulations 
are amended in 21 CFR 522.970 to reflect the approval.
    In accordance with the freedom of information provisions of 21 CFR 
part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and 
effectiveness data and information submitted to support approval of 
this application may be seen in the Division of Dockets Management 
(HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, 
Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.
    The agency has determined under 21 CFR 25.33 that this action is of 
a type that does not individually or cumulatively have a significant 
effect on the human environment. Therefore, neither an environmental 
assessment nor an environmental impact statement is required.
    This rule does not meet the definition of ``rule'' in 5 U.S.C. 
804(3)(A) because it is a rule of ``particular applicability.'' 
Therefore, it is not subject to the congressional review requirements 
in 5 U.S.C. 801-808.

List of Subjects in 21 CFR Part 522

    Animal drugs.

0
Therefore, under the Federal Food, Drug, and Cosmetic Act and under 
authority delegated to the Commissioner of Food and Drugs and 
redelegated to the Center for Veterinary Medicine, 21 CFR part 522 is 
amended as follows:

PART 522--IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

0
1. The authority citation for 21 CFR part 522 continues to read as 
follows:

    Authority: 21 U.S.C. 360b.

0
2. In Sec.  522.970, revise paragraphs (b)(1) and (b)(4) to read as 
follows:


Sec.  522.970  Flunixin.

* * * * *
    (b) * * *
    (1) See Nos. 000061, 055529, and 061623 for use as in paragraph (e) 
of this section.
* * * * *
    (4) See No. 059130 for use as in paragraphs (e)(1) and (e)(2) of 
this section.
* * * * *

    Dated: March 12, 2010.
Bernadette Dunham,
Director, Center for Veterinary Medicine.
[FR Doc. 2010-6038 Filed 3-18-10; 8:45 am]
BILLING CODE 4160-01-S

